Allweiss L. Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial. PS-162.
Ruxolitinib leidt niet tot betere uitkomst bij opgenomen COVID-19-patiënt
mei 2022 | Pneumonie, Virale infecties